BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...

AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

On October 18 th (CET), the CHMP issued a recommendation for approval, further advancing DMB-3115’s journey toward the European Union. The CHMP evaluates medicinal products based on scientific ...

WARREN, N.J., Oct. 18, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued positive opinions recommending an extended authorization for ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the PD-1 inhibitor be used in combination with platinum- and fluoropyrimidine-based chemotherapy to treat adults with ...

with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated ...